Hemodynamics and Survival in Patients With Pulmonary Arterial Hypertension Related to Systemic Sclerosis*
Authors:
- Steven M. KawutSKSteven M. Kawut
- Darren B. TaichmanDTDarren B. Taichman
- Christine L. Archer-ChickoCAChristine L. Archer-Chicko
- Harold I. PalevskyHPHarold I. Palevsky
- Stephen E. KimmelSKStephen E. Kimmel
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Hemodynamic Effects of Epoprostenol in Patients With Systemic Sclerosis and Pulmonary HypertensionChest, 2000
- Fine Specificity of Anti‐Fibrillin‐1 Autoantibodies in Primary Pulmonary Hypertension SyndromeScandinavian Journal of Immunology, 2000
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case SeriesAnnals of Internal Medicine, 1999
- PULMONARY HYPERTENSION IN SYSTEMIC AUTOIMMUNE DISEASERheumatic Disease Clinics of North America, 1997
- The pulmonary pathologic manifestations of the CREST syndromeHuman Pathology, 1990
- Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.Circulation, 1989
- Pulmonary hypertension in the crest syndrome variant of systemic sclerosisArthritis & Rheumatism, 1986
- Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosisThe American Journal of Medicine, 1983
- Pulmonary Hypertension in the CREST Syndrome Variant of Progressive Systemic Sclerosis (Scleroderma)Annals of Internal Medicine, 1977